Experimental burn wound sepsis--evaluation of enzymatic debridement.
D000818:Animals; D001412:Bacillus subtilis; D002056:Burns / Q000188:drug therapy*; D003646:Debridement; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D008297:Male; D008722:Methods; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000472:pathogenicity; D051381:Rats; D012834:Silver / Q000627:therapeutic use; D013381:Subtilisins / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013552:Swine; D014105:Tosyl Compounds / Q000627:therapeutic use; D014774:Virulence; D014946:Wound Infection / Q000188:drug therapy* / Q000382:microbiology
D013449:Sulfonamides; D014105:Tosyl Compounds; D013411:Sulfadiazine; D012834:Silver; D010450:Endopeptidases; D013381:Subtilisins